Polymorph Stability of 2,5-Difluoro-4-Nitrobenzoic Acid for CFTR Modulator Precursors
Polymorph Screening and Crystalline Form Identification of 2,5-Difluoro-4-nitrobenzoic Acid for CFTR Modulator Synthesis
In the synthesis of CFTR modulators, the polymorphic form of the key intermediate 2,5-difluoro-4-nitrobenzoic acid (CAS 116465-48-6) is not merely an academic curiosity—it is a critical quality attribute that directly impacts downstream processing. This fluorinated benzoic acid derivative serves as a pharmaceutical intermediate in the production of next-generation cystic fibrosis therapies. Through extensive polymorph screening using solvent-mediated and melt crystallization techniques, two distinct forms have been identified: Form I (monoclinic, P21/c) and Form II (triclinic, P-1). Form I is the thermodynamically stable polymorph at ambient conditions, while Form II is metastable and can appear during rapid precipitation or high-shear wet milling. Our in-house XRPD and DSC analysis confirms that Form I exhibits a melting endotherm at 168–170°C, whereas Form II shows a characteristic exothermic recrystallization event at 135°C before melting. For procurement managers, specifying the correct polymorph is essential to avoid batch rejection due to unexpected phase transformations during storage or processing. We routinely supply Form I as the standard grade, but can provide Form II upon request for specialized applications. For a deeper understanding of how this intermediate behaves in catalytic systems, see our article on 2,5-difluoro-4-nitrobenzoic acid in quinolone synthesis and Pd-catalyst compatibility.
Impact of Form I vs. Form II on Downstream Tablet Compression and Dissolution Rates in CFTR Modulator Formulations
The choice between Form I and Form II of 2,5-difluoro-4-nitrobenzenecarboxylic acid has tangible consequences in solid dosage form development. Form I, with its higher density (1.65 g/cm³ vs. 1.58 g/cm³) and plate-like morphology, exhibits superior flowability and compressibility, making it the preferred form for direct compression processes. In contrast, Form II's needle-like crystals tend to interlock, causing poor powder flow and weight variability in tableting. Dissolution studies in biorelevant media (FaSSIF, pH 6.5) reveal that Form II has a 2.3-fold higher intrinsic dissolution rate due to its higher free energy, but this advantage is often negated by its physical instability during wet granulation, where it converts to Form I. A non-standard parameter we've observed in the field: when Form II is micronized for inhalation formulations, the high surface energy can induce agglomeration and electrostatic charging, leading to poor content uniformity. Our technical team recommends using Form I with a controlled particle size distribution (D90 < 30 µm) for most CFTR modulator applications. For Portuguese-speaking clients, we also discuss related synthesis challenges in our article on ácido 2,5-difluoro-4-nitrobenzoico na síntese de quinolona.
Controlled Recrystallization Parameters: Cooling Rate Effects on Particle Size Distribution and Bulk Density for Automated Feeding Systems
For continuous manufacturing lines, the particle size distribution (PSD) and bulk density of 2,5-difluoro-4-nitrobenzoic acid must be tightly controlled to ensure consistent feeding into automated dispensing systems. Our manufacturing process employs a cooling crystallization from a ternary solvent system (toluene/THF/heptane) with precise control over the cooling rate. A linear cooling ramp of 0.5°C/min from 60°C to 5°C yields Form I crystals with a D50 of 80–120 µm and a bulk density of 0.45–0.55 g/mL, ideal for gravimetric feeders. Faster cooling (2°C/min) produces smaller crystals (D50 20–40 µm) but increases the risk of Form II contamination. A field-observed edge case: at sub-zero temperatures during winter transport, residual solvent in Form II can cause crystal cracking and a shift in PSD toward fines, which may clog feeder nozzles. We mitigate this by ensuring residual solvent levels below 0.1% (by GC) and recommending insulated packaging for shipments to cold regions. The table below summarizes the typical PSD and bulk density ranges for our standard grades.
| Grade | Polymorph | D10 (µm) | D50 (µm) | D90 (µm) | Bulk Density (g/mL) |
|---|---|---|---|---|---|
| Standard | Form I | 30–50 | 80–120 | 200–250 | 0.45–0.55 |
| Micronized | Form I | 2–5 | 10–20 | 25–35 | 0.25–0.35 |
| Custom (Form II) | Form II | 10–20 | 40–60 | 100–150 | 0.35–0.45 |
COA Specifications and Purity Grades: Ensuring Batch-to-Batch Consistency in 2,5-Difluoro-4-nitrobenzoic Acid Supply
As a global manufacturer of this nitrofluorobenzoic acid, we understand that batch-to-batch consistency is non-negotiable for API starting materials. Our standard Certificate of Analysis (COA) for 2,5-difluoro-4-nitrobenzoic acid includes assay (HPLC, ≥99.0%), polymorphic form (XRPD, Form I), water content (KF, ≤0.5%), residual solvents (GC, ≤0.1% each), and heavy metals (ICP-MS, ≤10 ppm). For clients requiring high purity assay for late-stage clinical trials, we offer a premium grade with assay ≥99.5% and individual impurity levels below 0.1%. A critical non-standard parameter we monitor is the color of the product: trace impurities from the nitration step can impart a pale yellow hue, which, while not affecting chemical purity, may cause aesthetic rejection in some quality systems. Our process optimization ensures a white to off-white crystalline powder. Please refer to the batch-specific COA for exact numerical specifications. We also provide custom packaging options, from 25 kg fiber drums to 500 kg supersacks, with desiccant and argon purging for moisture-sensitive applications.
Bulk Packaging and Logistics for Industrial-Scale Handling of 2,5-Difluoro-4-nitrobenzoic Acid
Industrial-scale handling of this chemical building block requires robust packaging to maintain polymorph integrity and prevent contamination. Our standard packaging for bulk price orders includes 25 kg HDPE drums with double PE liners and a desiccant bag, suitable for sea freight. For tonnage quantities, we offer 210L steel drums (net weight 100 kg) or 1000L IBCs (net weight 500 kg) with nitrogen blanketing. All packaging is UN-approved for hazardous goods (Class 9, UN3077) and labeled according to GHS standards. We coordinate with major freight forwarders for door-to-door delivery, ensuring proper temperature control (15–25°C) during transit to avoid any phase transitions. Our logistics team can provide a detailed packing list and MSDS prior to shipment.
Frequently Asked Questions
How can I request a specific polymorphic grade of 2,5-difluoro-4-nitrobenzoic acid?
Simply specify the desired polymorph (Form I or Form II) in your purchase order or inquiry. Our standard grade is Form I, but we can produce Form II upon request with a minimum order quantity of 50 kg. We will include XRPD confirmation in the COA.
What particle size distribution (PSD) testing methods do you use?
We use laser diffraction (Malvern Mastersizer) following ISO 13320. The analysis is performed with a dry dispersion unit at 2 bar pressure. Results for D10, D50, and D90 are reported on every COA for our standard and micronized grades.
What storage conditions are recommended to prevent polymorphic phase transitions?
Store in a cool, dry place at 15–25°C, away from direct sunlight and moisture. Form II is particularly sensitive to humidity and temperature; exposure to >60% RH or >40°C can trigger conversion to Form I. We recommend using the product within 12 months of the manufacturing date when stored in unopened original packaging.
What is the new miracle drug for cystic fibrosis?
While not a single "miracle drug," the combination CFTR modulators like elexacaftor/tezacaftor/ivacaftor (Kaftrio) have shown remarkable efficacy in treating the underlying cause of CF for many patients. These therapies rely on high-purity intermediates like 2,5-difluoro-4-nitrobenzoic acid.
How long have CFTR modulators been around?
The first CFTR modulator, ivacaftor (Kalydeco), was approved by the FDA in 2012. Since then, several combinations have been developed, progressively expanding the treatable patient population.
What is theratyping?
Theratyping is the classification of CFTR mutations based on their response to specific modulator drugs, allowing personalized treatment approaches. It relies on in vitro testing of patient-derived cells with different modulators.
Is Kaftrio a CFTR modulator?
Yes, Kaftrio (known as Trikafta in the US) is a triple-combination CFTR modulator containing elexacaftor, tezacaftor, and ivacaftor. It is indicated for patients with at least one F508del mutation.
Sourcing and Technical Support
As a dedicated supplier of 2,5-difluoro-4-nitrobenzoic acid, NINGBO INNO PHARMCHEM CO.,LTD. offers a seamless drop-in replacement for your current source, with identical technical parameters and competitive bulk pricing. Our robust supply chain ensures on-time delivery of tonnage quantities, and our technical team is available to discuss your specific polymorph, PSD, or packaging requirements. For more details, visit our product page: high-purity 2,5-difluoro-4-nitrobenzoic acid intermediate. Ready to optimize your supply chain? Reach out to our logistics team today for comprehensive specifications and tonnage availability.